The OFF-X portal uses cookies. You can change your cookie preferences in your browser settings. If you agree to the use of cookies, please click OK. For more information on our use of cookies, please see our Cookie Policy.


Unexpected toxicity and safety issues constitute one of the most disruptive events in drug R&D, with one third of drug attrition still directly related to these events. In this context, a translational approach to drug safety and prompt access to actionable safety intelligence can significantly reduce patient burden and avoid costly failures.

Since 2017, the OFF-XTM portal has been supporting translational researchers in pharmaceutical and healthcare organizations to de-risk drug R&D programs.

By delivering critical integrated preclinical toxicity and clinical adverse event intelligence coupled to advanced analytics, OFF-XTM allows safety liabilities to be monitored and anticipated across all phases of drug R&D and post-marketing

Rapid access to actionable safety intelligence via OFF-X provides a critical competitive advantage for your R&D:

Contact us today to arrange a demonstration and request a 2 week trial